Centre tells Delhi HC: Zydus Cadila's COVID vaccines for children may be available in near future

Rs 150 per dose is not sustainable in long run: Bharat Biotech on Centre's Covaxin price

Hyderabad-based vaccine maker Bharat Biotech on Tuesday said the current supply price of its Covid-19 vaccine Covaxin to the Centre is not sustainable in the long run.

COVID-19: Government extends help to Indian students studying abroad now stuck in country

Clinical trial of Bharat Biotech's Covaxin on children begins at AIIMS Patna

Students heading to universities abroad can get vaccines at walk-in centres in Mumbai

Delhi high court refuses to stay Covaxin clinical trial on children aged 2-18

DCGI allows Phase II-III clinical trial of Covaxin on 2 to 18-years-old

Covaxin trials approved in children between 2 and 18 years

Manish Sisodia: Bharat Biotech says can’t give additional Covaxin doses to Delhi

Karnataka to get 2 crore COVID-19 vaccine doses through global tender